Description

Cagrilintide 10mg For Sale — Amylin Analogue Research Peptide

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a pancreatic peptide co-secreted with insulin that plays a key role in postprandial glucose regulation, gastric emptying inhibition, and satiety signaling. Cagrilintide’s extended half-life (approximately 7 days) makes it a practical tool for chronic dosing research protocols.

Research Profile

Cagrilintide is being studied as a combination therapy partner — most notably with semaglutide in the CagriSema combination — with Phase 3 data showing additive weight reduction effects beyond either compound alone. Researchers studying amylin receptor biology, combination incretin approaches, and metabolic syndrome models have cited cagrilintide as a key contemporary research compound. The 10mg vial format supports extended research protocols.